Skip to content

Home
Team
Portfolio
News
- TCG News
- Portfolio News
Careers
Contact

Menu

Home
Team
Portfolio
News
- TCG News
- Portfolio News
Careers
Contact

September 2019

Constellation Pharmaceuticals Advances CPI-0209 into Clinical Trials, Expanding its EZH2 Franchise

Portfolio News / By admin

September 24, 2019

REVOLUTION Medicines Announces Dosing of First Patient in RMC-4630-02, a Phase 1b/2 Trial Combining RMC-4630 with a MEK Inhibitor

Portfolio News / By admin

September 17, 2019

Ribon Therapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of RBN-2397, a First-In-Class PARP7 Inhibitor

Portfolio News / By admin

September 4, 2019

Kallyope Inc. Appoints Juha Lauren as Chief Business Officer

Portfolio News / By admin

September 4, 2019

Ribon Therapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of RBN-2397, a First-In-Class PARP7 Inhibitor

Portfolio News / By admin

September 4, 2019

Accent Therapeutics Appoints Shakti Narayan as Chief Executive Officer

Portfolio News / By admin

September 3, 2019

Search for:

Recent Posts

Revolution Medicines Announces Commencement of Public Offering of Common Stock
NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2022 Financial Results
Revolution Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Update on Corporate Progress
eFFECTOR Therapeutics Announces Positive Top-Line Results from Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID
Neurona Therapeutics Announces FDA Clearance of Expanded Inclusion Criteria for Phase I/II Clinical Trial of NRTX-1001 Regenerative Cell Therapy in Patients with Dominant Hemisphere Drug-Resistant Focal Epilepsy

Recent Comments

Archives

Categories

Portfolio News
TCG News

The Column Group

Copyright © 2022. The Column Group | Privacy Policy | Terms of Use
Website developed by CP Communications

Scroll to Top